Literature DB >> 12163165

Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target.

Kouhei Tsumoto1, Satoru Misawa, Yoichi Ohba, Takamasa Ueno, Hideya Hayashi, Nobuhiro Kasai, Hideki Watanabe, Ryutaro Asano, Izumi Kumagai.   

Abstract

We have synthesized and characterized peptides derived from complementarity-determining regions (CDRs) of 8D4, a mouse monoclonal antibody against NS3 protease domain of hepatitis C virus. 8D4 inhibits enzymatic activity without its cofactor, NS4A peptide. One of the synthetic peptides derived from CDRs, CDR1 of the heavy-chain (CDR-H1) peptide strongly inhibited NS3 protease activity competitively in the absence of NS4A and non-competitively in the presence of NS4A. Moreover, cyclic CDR-H1 peptides bridged by disulfide inhibited NS3 protease more potently. The chain length of the CDR-H1 peptide is critical for strong inhibition, even when the peptide is circularized. This finding suggests the importance of peptide conformation. In contrast to a cognate antibody molecule, CDR-derived peptides may provide good ligands for target molecules by having a tolerance to conformational changes of the targets caused by cofactor binding or mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163165     DOI: 10.1016/s0014-5793(02)03090-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  Bioactive peptides based on diversity libraries, supramolecular chemistry and rational design: a new class of peptide drugs. Introduction.

Authors:  Rob Meloen; Peter Timmerman; Hans Langedijk
Journal:  Mol Divers       Date:  2004       Impact factor: 2.943

Review 2.  The structural basis of antibody-antigen recognition.

Authors:  Inbal Sela-Culang; Vered Kunik; Yanay Ofran
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.